Ovarian Cancer PBMC
About: Ovarian Cancer PBMC samples are collected from clinically confirmed ovarian cancer donors and cryopreserved. These PBMCs are ideal for immune profiling, biomarker discovery, and functional assays.
| Lot Number | Condition | Cell Count (M) | Race/Ethnicity | Age | Gender | Country of Collection | Medications | Vials | Price | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| 56298 | Ovarian Cancer | 10M | Caucasian | 53 | Female | United States (US) |
welbutrin QD generic seteria for adhd QD
|
12 | ||
| 56372 | Ovarian Cancer | 10M | African American | 73 | Female | United States (US) |
astovorstatin 10 mg QD lexapro 20 mg QD fenofibrate 48 mg QD hydrolazine 25 mg QD losartan 100 mg QD Metropol 25 gm qD potasium 20 naq QD synthroid 125 mg QD Vit D 50 mg QD nesium 140 mg QD creon QD tramadiol 50 mg PRN
|
1 | ||
| 54764 | Ovarian Cancer | 10M | Caucasian | 77 | Female | United States (US) |
Xarelto 20 mg QD mobic (arthritis) QW synthroid 125 mcg QD losartan 1 mg QD oxybutynin ER QD Ativan QPM Vit D2 50,000 unit BIM
|
1 | ||
| 51619 | Ovarian Cancer | 10M | Caucasian | 60 | Female | United States (US) |
letrozole 2.5 mg QD metformin 250 BID mounjaro QW levothyroxine 50 mg QD
|
1 | ||
| 50609 | Ovarian Cancer | 10M | Caucasian | 61 | Female | United States (US) |
gabitril QD duloxetine 60mg QD lisinopril QD omeprazole 20 mg QD loperamide 4mg QD
|
3 | ||
| 49067 | Ovarian Cancer | 10M | Asian/Pacific IslanderOther | 62 | Female | United States (US) |
lisinopril/10mg QD atorvastatin/20mg QD Vitamin D3/500iu/ QD melatonin/3mg/QD metformin 1000mg QD OTC supliments allertech, lurotydine, phintinbasol, pectin, metamucil
|
5 | ||
| 48032 | Ovarian Cancer | 10M | Caucasian Native American | 65 | Female | United States (US) |
gabapentin/300mg/TID omperazol/40mg/BID meloxicam/15 mg/QD potassium/80ml equilivents/BID Zyrtec/10mg/QD stool softener multi vits OTC lynparza 300 mg BID
|
1 |
High-Quality Ovarian Cancer PBMC for Research
Ovarian Cancer PBMC are sourced from donors clinically diagnosed with ovarian cancer and processed under stringent conditions to support research. These cryopreserved peripheral blood mononuclear cells (PBMCs) enable studies on immune dysregulation, cytokine response, and therapeutic screening for ovarian cancer-related inflammation.
Product Features
- Research Use Only (RUO), cryopreserved PBMCs
- Clinically confirmed Ovarian Cancer donors
- Available in cell counts ranging from 5 million to 2 billion
- Processed within 24 hours of collection
- Stored using CryoStor® CS10 freezing media
- IRB-approved protocols and electronic informed consent
- Screen LeukoLot™ available prior to bulk orders
De-identified Donor Data
- Verified Ovarian Cancer diagnosis
- Donor demographics: age, sex assigned at birth, race/ethnicity
- Self-reported allergies and infectious disease history
- Additional Ovarian Cancer-specific data available upon request
Applications
- Biomarker discovery and validation
- Drug screening and therapeutic development
- Immune pathway analysis in Ovarian Cancer pathophysiology
- Transcriptomic and proteomic profiling
Quality and Compliance
- IRB-approved collections and protocols
- 21 CFR Part 11 – compliant e-consent system
- HIPAA-compliant donor data protection
Ordering & Shipping
Ovarian Cancer PBMC samples are shipped on dry ice and available in custom aliquots. For international orders or regulatory requirements, please contact learnmore@sanguinebio.com to confirm documentation and compliance needs.
Protocols & Documentation
-
Download
PBMC Isolation from Whole Blood
Standard operating procedure for isolating peripheral blood mononuclear cells from whole blood using density-gradient separation.
-
Download
Immune Cell Isolation
Guidelines for isolating immune cell populations with validated enrichment steps, purity checkpoints, and documentation.
-
Download
Choosing the Right PBMC Configuration
Reference guide comparing PBMC formats, cryopreservation states, and study-fit recommendations for your application.
-
Download
Thawing Cryopreserved PBMC
Validated thawing protocol to recover viable cryopreserved PBMCs while minimizing activation and loss of function.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
PBMC
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – with the exception of GMP leukopaks, all our products are research use only (RUO).
1 Answer
Our complete catalog can be found here: https://sanguinebio.com/products/
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective colleciton services to tailored to fit your research. For more information and request a quote, please see: https://sanguinebio.com/prospective-biospecimen-collection-services/
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory which can be found here https://sanguinebio.com/products/?pro_inventory=inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: https://sanguinebio.com/quality-and-compliance/
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom PBMC cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.